"The management and shareholders of Fumapharm AG deserve credit for identifying this breakthrough therapy that has the potential to improve the lives of thousands of patients with relapsing-remitting multiple sclerosis.
"We are also pleased to have been able to offer the former Fumapharm shareholders an opportunity to realize immediate liquidity for a portion of their interest in the Fumapharm earn-out, and to mitigate the risks associated with owning such a concentrated financial asset."
Pablo Legorreta, Founder & Chief Executive Officer, Royalty Pharma
At a Glance
Approved for the oral treatment of psoriasis, and is the only compound in clinical trials for the treatment of MS known to activate the Nrf2 pathway. Early stage research suggests that Tecfidera has the potential to reduce the activity and impact of inflammatory cells on the central nervous system (CNS) and may induce direct cytoprotective responses in CNS cells. These effects may enhance the CNS cells’ ability to mitigate the toxic inflammatory and oxidative stress that play a role in MS pathophysiology.
The efficacy of Tecfidera has been evaluated in two global Phase 2 clinical trials, DEFINE and CONFIRM. Results show that Tecfidera administered two or three times daily, demonstrated efficacy across a number of critical endpoints vs. placebo at two years, as well as favorable safety and tolerability profiles.
Applications In Development: